Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novasep Acquires Bioprocess Development Specialist and Contract Manufacturer Henogen

Published: Wednesday, July 08, 2009
Last Updated: Wednesday, July 08, 2009
Bookmark and Share
Acquisition of upstream processing capabilities and services enables Novasep to offer full-range of biomanufacturing solutions.

Novasep, a producer of active pharmaceutical ingredients (APIs) and purification technologies for the life science industries, announces today the acquisition of Henogen, a contract manufacturing organization (CMO) offering bioprocess development and manufacturing services from the cell bank to the supply of clinical products.

The move adds a complementary, range of upstream processing capabilities and services to Novasep's comprehensive downstream processing (DSP) offer. Financial terms of the transaction were not disclosed.

As a result of this acquisition, Novasep customers will have access to manufacturing solutions covering almost every type of biopharmaceutical. In particular, Henogen brings its experience with an extensive array of expression tools including E. coli, yeast, L. lactis, insect and mammalian cells as well as viral vectors.

Novasep also becomes one of the few contract manufacturing organizations worldwide able to provide the complete manufacturing solution in the growing field of antibody-drug conjugates, covering early development to future commercial production.

Novasep now offers a combination of solutions for biopharmaceutical manufacturing. These include:
 
• Bioprocess development - both upstream and downstream processing
 
• An out-sourcing solution - contract biomanufacturing services, from the cell bank to the vial
 
• An in-sourcing solution - chromatography and membrane filtration technologies and complete DSP, from lab to industrial scale

"Novasep is making another strategic step forward with the acquisition of Henogen," said Dr Roger-Marc Nicoud, president & CEO of Groupe Novasep SAS. "The two companies have an excellent range of complementary capabilities and we look forward to offering our customers an even wider range of manufacturing services. The move is further confirmation of Novasep's determination to become a major player in the world biomanufacturing market."

"Joining Novasep will provide a boost to the development of our business worldwide," said Dr Jean-François Pollet, CEO of Henogen SA. "We believe the combined offer of our two companies will be very attractive to our existing and future customers."

The two companies have already cooperated on several biomanufacturing projects and together have a strong portfolio of customers including big pharma, mid-size pharma and biotechs. Henogen has more than 100 employee and operates two biomanufacturing facilities south of Brussels. It will become a part of Novasep Process, Novasep's biomolecules division.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novasep Invests €10M to Reinforce its Bioconjugation Services
Expansion marks the company’s readiness for full range Antibody Drug Conjugates CMO services.
Thursday, June 25, 2015
Novasep Further Strengthens Management Team
Pierre-Louis Mikus joins as chief legal officer and Bertrand Waymel is promoted to group human resources director.
Wednesday, May 06, 2015
Novasep and Celladon Execute MYDICAR API Supply Agreement
An innovative, genetically-targeted enzyme replacement therapy based on AAV1/SERCA2a.
Thursday, March 26, 2015
Novasep & Celladon Partner
Novasep has entered into an agreement with Celladon, to commercially biomanufacture Celladon’s Mydicar API.
Tuesday, February 24, 2015
Novasep Enters into an Agreement with Celladon
Company selected to commercially biomanufacture Celladon's Mydicar API.
Thursday, February 19, 2015
Novasep Opens New Office in Thailand
Novasep’s extended presence in South East Asia strengthens the company’s ability to address growing needs in the region’s food and feed markets.
Saturday, December 27, 2014
Novasep to Sell its Bahamian Plant to Local Investor
Company has completed the sale of the Bahamian facility and related business of its fully-owned subsidiary, Pharmachem.
Thursday, October 09, 2014
Novasep Passes FDA Inspections on Two Sites
Novasep wins approval to produce new molecular entity for US market.
Thursday, July 24, 2014
Novasep’s €4 M ADC Manufacturing Plant Extension Commissioned
The new Highly Potent API manufacturing capacity at the Le Mans facility will boost Novasep’s ability to meet customer demand for producing anti-cancer therapies.
Friday, May 16, 2014
Novasep Reports Full Year 2013 Results
Results show strong growth and beating guidance.
Friday, March 28, 2014
Novasep Appoints CEO Michel Spagnol as Chairman
Novasep presents strategic developments.
Wednesday, March 05, 2014
Novasep Expands and Opens Subsidiary in India
Subsidiary to meet India’s increasing need for high efficacy processes for its fast growing food and feed industries.
Friday, February 14, 2014
Novasep Attracts Top Talent to Complete its Executive Team
Thierry Van Nieuwenhove, a seasoned CMO top executive, joins Novasep as president of the Synthesis Business Unit.
Monday, January 20, 2014
Novasep Expands and Opens Subsidiary in India
Novasep Process Engineering Services PVT LTD will meet India’s increasing need for high efficacy processes for its fast growing food and feed industries.
Monday, December 16, 2013
Novasep Opens Indian Subsidiary
New office will meet India’s increasing need for high efficacy processes for its fast growing food and feed industries.
Tuesday, December 10, 2013
Scientific News
Study Finds Brain Chemicals that Keep Wakefulness in Check
Researchers to develop new drugs that promote better sleep, or control hyperactivity in people with mania.
Sorting Through Cellular Statistics
Aaron Dinner, professor in chemistry, and his graduate student Herman Gudjonson are trying to read the manual of life, DNA, as part of the Dinner group’s research into bioinformatics—the application of statistics to biological research.
Playing 'Tag' with Pollution lets Scientists See Who's It
Using a climate model that can tag sources of soot from different global regions and can track where it lands on the Tibetan Plateau, researchers have determined which areas around the plateau contribute the most soot — and where.
Women’s Immune System Genes Operate Differently from Men’s
A new technology reveals that immune system genes switch on and off differently in women and men, and the source of that variation is not primarily in the DNA.
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
High-Resolution 3D Images Reveal the Muscle Mitochondrial Power Grid
NIH mouse study overturns scientific ideas on energy distribution in muscle.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!